SWTX
SpringWorks Therapeutics, Inc. · Healthcare · Biotechnology
Momentum inputs (comparable managers):
holder breadth -23.1% ·
share flow -18.8% ·
net new positions -20.0%
— formula
Broad distribution — falling shares and fewer holders
All ownership figures: tracked 13F managers only, common-stock positions, reporting period Q4 2024
| # | Manager | Shares | Δ shares | Value | Their weight | Held | ||
|---|---|---|---|---|---|---|---|---|
| 1 | T. Rowe Price ✦ | 3.27M | -6.9% | $118.32M | 0.0% | ▼ Trim | 3 | SEC ↗ ×2 |
| 2 | State Street Global Advisors ✦ (passive) | 3.00M | — | $108.43M | 0.0% | n/c | 1 | SEC ↗ |
| 3 | Geode Capital Management ✦ (passive) | 1.67M | 0.0% | $60.36M | 0.0% | ▼ Trim | 3 | SEC ↗ ×2 |
| 4 | Duquesne Family Office ✦ | 859.69K | +21.9% | $31.06M | 0.9% | ▲ Add | 3 | SEC ↗ |
| 5 | Soros Fund Management ✦ | 600.47K | +7.4% | $21.69M | 0.5% | ▲ Add | 3 | SEC ↗ |
| 6 | D. E. Shaw & Co. ✦ | 387.73K | -46.5% | $14.01M | 0.0% | ▼ Trim | 3 | SEC ↗ |
| 7 | Citadel Advisors ✦ | 373.23K | +185.6% | $13.48M | 0.0% | ▲ Add | 3 | SEC ↗ ×2 |
| 8 | Norges Bank ✦ (passive) | 186.50K | -20.1% | $6.74M | 0.0% | ▼ Trim | 3 | SEC ↗ |
| 9 | Wellington Management ✦ | 31.18K | -10.9% | $1.13M | 0.0% | ▼ Trim | 3 | SEC ↗ ×4 |
| 10 | AQR Capital Management ✦ | 20.88K | -52.5% | $754,431 | 0.0% | ▼ Trim | 3 | SEC ↗ ×3 |
“Their weight” = the position's share of that manager's reported 13F equity value — the conviction measure. ✦ = curated manager.
New buyers
| No new tracked buyers this quarter. |
Exited
| Marshall Wace | $62.86M | was 0.1% |
| Two Sigma Investments | $4.91M | was 0.0% |
| Millennium Management | $2.42M | was 0.0% |
Full-market context: across ALL 13F filers (SEC structured data, Q1 2026): 1 holders, 1 shares, $47 reported. This is a different, older period than the tracked-universe figures above and the two are never mixed.
What else this security's tracked holders most often hold — shared-ownership counts, not fundamental relationships.